This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Both infliximab and adalimumab were found to be effective in achieving remission and enhancing quality of life while having a high level of tolerability in patients with mucocutaneous Behçet syndrome.
Medscape Medical News